CD274 and non-small cell lung carcinoma: In this study, we included advanced NSCLC patients on ICI monotherapy only to minimize treatment heterogeneity in the study population, and remained consistent with the SITC definition of primary resistance, where only patients treated with systemic anti-PD1 or anti-PD-L1 monotherapy were included [19].